What Oddity Tech (ODD)'s Move Into AI-Powered Telehealth Means for Shareholders

• Earlier this month, Oddity Tech Ltd. announced its expansion into medical-grade prescription and over-the-counter healthcare with the upcoming Brand 3 telehealth platform, which leverages AI-powered personalized dermatology treatment plans and its large user base.
• This move marks a significant broadening of Oddity Tech’s reach beyond beauty, signaling an ambition to become a leader at the intersection of digital health and consumer wellness.
• We now explore how Oddity Tech’s entry into telehealth and AI-driven dermatology treatments could reshape its growth outlook and sector positioning.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Oddity Tech Investment Narrative Recap

To believe in Oddity Tech as a shareholder, you need to trust the company’s ability to expand its digital-first, AI-powered model into new health and wellness markets, leveraging its existing user base to drive both incremental growth and long-term relevance. The Brand 3 telehealth launch adds immediate visibility to short-term catalysts, supporting hopes for new revenue streams, while the greatest near-term risk remains the challenge of sustaining digital customer acquisition efficiency as Oddity pursues broader ambitions; the impact from this news reinforces the significance of execution, but does not materially shift this core risk balance.

Among recent updates, Oddity’s completion of a US$100,000,000 buyback earlier this year stands out as particularly relevant: it demonstrates management’s confidence in the underlying growth strategy fueled by product and market expansion, which now includes the Brand 3 telehealth platform that could further accelerate revenue momentum and diversify future earnings as new brands go to market.

However, it’s important for investors to recognize that, in contrast, digital customer acquisition costs and shifting online engagement trends present sustainability challenges that could ...

Read the full narrative on Oddity Tech (it's free!)

Oddity Tech's narrative projects $1.3 billion in revenue and $177.0 million in earnings by 2028. This requires 19.0% yearly revenue growth and a $66.9 million earnings increase from $110.1 million today.

Uncover how Oddity Tech's forecasts yield a $73.20 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members set Oddity Tech’s fair value between US$58.79 and US$88.92 across six independent estimates. With digital growth and customer acquisition costs pivotal to future performance, readers can see just how differently opinions on the company’s outlook can vary.

Explore 6 other fair value estimates on Oddity Tech - why the stock might be worth as much as 46% more than the current price!

Build Your Own Oddity Tech Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Oddity Tech research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Oddity Tech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Oddity Tech's overall financial health at a glance.

Curious About Other Options?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com